BTC Capital Management Inc. Purchases 1,172 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

BTC Capital Management Inc. grew its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 12.4% in the fourth quarter, Holdings Channel.com reports. The firm owned 10,623 shares of the specialty pharmaceutical company’s stock after buying an additional 1,172 shares during the period. BTC Capital Management Inc.’s holdings in ANI Pharmaceuticals were worth $587,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently modified their holdings of the company. KBC Group NV lifted its holdings in ANI Pharmaceuticals by 89.2% during the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock worth $70,000 after purchasing an additional 600 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of ANI Pharmaceuticals by 24.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after buying an additional 579 shares during the period. Susquehanna Fundamental Investments LLC purchased a new stake in shares of ANI Pharmaceuticals in the second quarter worth about $228,000. HighTower Advisors LLC bought a new position in shares of ANI Pharmaceuticals in the third quarter valued at approximately $222,000. Finally, Marshall Wace LLP purchased a new position in ANI Pharmaceuticals during the second quarter valued at approximately $253,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Insider Activity

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the sale, the chief financial officer now owns 154,468 shares in the company, valued at approximately $8,617,769.72. The trade was a 4.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total value of $60,000.00. Following the sale, the senior vice president now directly owns 49,059 shares of the company’s stock, valued at approximately $2,943,540. This trade represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 42,381 shares of company stock valued at $2,441,556. Corporate insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Trading Down 1.5 %

Shares of ANIP stock opened at $58.64 on Friday. The business has a 50-day moving average price of $56.61 and a two-hundred day moving average price of $58.60. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $70.81. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The firm has a market cap of $1.23 billion, a P/E ratio of -106.62 and a beta of 0.73.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The company had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. During the same quarter in the previous year, the company posted $1.05 EPS. ANI Pharmaceuticals’s quarterly revenue was up 12.5% compared to the same quarter last year. Equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have issued reports on ANIP. Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Piper Sandler started coverage on ANI Pharmaceuticals in a research report on Friday, October 11th. They set an “overweight” rating and a $68.00 target price for the company. StockNews.com cut ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, ANI Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $77.71.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.